Mersana Therapeutics (MRSN) to Release Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $2.30 million for the quarter, compared to analysts' expectations of $8.72 million. Mersana Therapeutics had a negative return on equity of 333.91% and a negative net margin of 349.98%. The company's revenue was down 78.3% compared to the same quarter last year. During the same period last year, the business posted ($0.47) earnings per share. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Trading Up 9.0 %

Shares of NASDAQ:MRSN traded up $0.21 during midday trading on Thursday, hitting $2.55. 1,941,790 shares of the stock traded hands, compared to its average volume of 1,604,763. The company has a quick ratio of 2.72, a current ratio of 2.72 and a debt-to-equity ratio of 2.02. The stock has a market capitalization of $312.83 million, a PE ratio of -2.93 and a beta of 1.50. Mersana Therapeutics has a one year low of $1.15 and a one year high of $6.28. The business's 50 day moving average is $1.90 and its two-hundred day moving average is $2.09.

Insiders Place Their Bets

In related news, CEO Martin H. Jr. Huber sold 50,423 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total value of $88,744.48. Following the transaction, the chief executive officer now directly owns 116,327 shares of the company's stock, valued at $204,735.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 70,849 shares of company stock worth $129,184. 11.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Citigroup decreased their target price on shares of Mersana Therapeutics from $6.00 to $5.00 and set a "buy" rating for the company in a research note on Tuesday, August 27th. Robert W. Baird cut their target price on Mersana Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 14th. Finally, Lifesci Capital raised Mersana Therapeutics to a "strong-buy" rating in a report on Monday, July 29th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Mersana Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.00.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.